Short answer
MapLight Therapeutics, Inc. (MPLT) filed an 8-K current report with the SEC on June 18, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). CFO Vishwas Setia separated immediately June 18, 2026 following a human resources violation.
MapLight Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- CFO Vishwas Setia separated immediately June 18, 2026 following a human resources violation
- Company states separation was unrelated to financial results, internal controls, clinical programs, or reporting practices
- No severance owed; agreement provides COBRA health coverage for up to three months
- Chief Administrative and Accounting Officer Jonathan Gillis appointed interim CFO and principal financial officer
- Gillis retains principal accounting officer role, concentrating finance leadership during transition
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other MapLight Therapeutics, Inc. 8-K filings
Get the next MPLT 8-K as it lands
Follow MPLT for push alerts, or ask the research agent what this filing means.